Dyne Therapeutics, Inc reports results for the quarter ended June 30 - Earnings Summary
Dyne Therapeutics, Inc reports results for the quarter ended June 30 - Earnings Summary
Dyne Therapeutics, Inc DYN.OQ reported a quarterly adjusted loss of $1.08 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -97 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -84 cents to -68 cents per share.
Reported revenue was zero; analysts expected zero.
Dyne Therapeutics, Inc's reported EPS for the quarter was a loss of $1.08.
The company reported a quarterly loss of $178.56 million.
Dyne Therapeutics, Inc shares had risen by 16.6% this quarter and gained 32.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.9% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Dyne Therapeutics, Inc is $40.00, about 35.3% above its last closing price of $25.90
This summary was machine generated from LSEG data July 29 at 10:44 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.75 | -1.08 | Missed |
Mar. 31 2026 | -0.77 | -0.73 | Beat |
Dec. 31 2025 | -0.77 | -0.76 | Beat |
Sep. 30 2025 | -0.84 | -0.76 | Beat |